Wang Xuan, Li Xue, Hou Shasha, Tan Jian, Zheng Wei. 131I therapy for differentiated thyroid carcinoma concurrent with active thyroid-associated ophthalmopathy and distant metastases: a case reportJ. Int J Radiat Med Nucl Med, 2026, 50(2): 117-123. DOI: 10.3760/cma.j.cn121381-202504017-00561
Citation: Wang Xuan, Li Xue, Hou Shasha, Tan Jian, Zheng Wei. 131I therapy for differentiated thyroid carcinoma concurrent with active thyroid-associated ophthalmopathy and distant metastases: a case reportJ. Int J Radiat Med Nucl Med, 2026, 50(2): 117-123. DOI: 10.3760/cma.j.cn121381-202504017-00561

131I therapy for differentiated thyroid carcinoma concurrent with active thyroid-associated ophthalmopathy and distant metastases: a case report

  • The authors report a case of differentiated thyroid carcinoma with postoperative recurrence complicating active thyroid-associated ophthalmopathy. While continuing levothyroxine sodium, the patient underwent 131I therapy combined with glucocorticoids, 99Tc-methylene diphosphonate, and targeted drugs as part of a comprehensive intervention, ultimately achieving a favorable prognosis. Based on a review of the literature, the authors aim to emphasize that clinicians should make flexible decisions according to the patient's specific condition, break through conventional therapeutic frameworks, and implement individualized treatment to maximize clinical benefits for the patient.
  • loading

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return